Placenta extract shows promise for liver health in early trial

NCT ID NCT05532124

Completed Disease control Sponsor: Green Cross Wellbeing Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 25, 2026 · Updated 11 times

Summary

This study tested a medicine made from human placenta, called LAENNEC, in 49 adults with chronic liver disease (fatty liver). The goal was to see if it is safe and can improve liver function. Participants received different doses or a placebo, and researchers measured side effects and changes in a key liver enzyme (ALT). The trial is complete, but results are not yet published.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Hanyang University Hospital.

Seoul, South Korea
Keimyung university dongsan medical center

Daegu, South Korea
Korea university guro hospital

Seoul, South Korea
Severance hospital

Seoul, South Korea
Soonchunhyang university hospital

Seoul, South Korea
Wonju severance christian hospital

Wŏnju, South Korea
Yeungnam university

Daegu, South Korea

Conditions

Explore the condition pages connected to this study.

CHRONIC LIVER DISEASE